Purpose: Endovascular mechanical thrombectomy using the AngioJet™ system can be considered to reestablish patency in occluded vascular access. The aim of this study was to review our results for endovascular mechanical thrombectomy using the AngioJet™ system in patients with arteriovenous fistulae (AVF) and arteriovenous grafts (AVG).
| INTRODUCTION
Adequate blood flow through hemodialysis arteriovenous (AV) access is mandatory to perform hemodialysis and prevent thrombosis in patients with end-stage renal disease. After creating arteriovenous fistula (AVF) or arteriovenous graft (AVG), prospective monitoring is performed to ensure functionality. 1 Regular follow-up in a protocolized surveillance program and aggressive treatment of access site stenosis to maintain patency of vascular access seem to be of paramount importance. Still, thrombosis of an AVF or AVG is not uncommon, with a higher incidence in AVGs compared with AVFs. For native fistulae, only one-third of the access events is observed compared with grafts. In surveillance programs, fistula thrombosis should not exceed 0.25 episodes per patient year, in grafts this number should not exceed 0.5. 1 A variety of techniques have been described for the treatment of vascular access thrombosis. Thrombus removal and treatment of the underlying stenosis are the main goals in reestablishing and maintaining patency. [2] [3] [4] The outcomes of surgical and endovascular intervention for vascular access thrombosis are comparable. 4 Surgical thrombectomy, pharmacological thrombolysis, balloon-assisted thrombectomy, aspiration, mechanical thrombectomy, or a combination of these techniques can be considered. 5 Endovascular mechanical thrombectomy using the AngioJet™ Peripheral Thrombectomy system (Boston Scientific, Natick, MA) can be deemed an effective technique, as described in a large multicenter registry for treatment of deep vein thrombosis. 6 Experience with this system in occluded vascular access is relatively limited though, especially in native AVF, with varying clinical success and patency rates. [2] [3] [4] [7] [8] [9] [10] [11] [12] Moreover, the quality of the evidence fluctuates. 13 The aim of this study was to review our 8-year experience in endovascular mechanical thrombectomy using the AngioJet™ system in patients with AVF and AVG, and to determine whether this can be deemed an effective technique. Outcomes were technical and clinical success and patency rates. Factors of influence on the patency after the AngioJet™ procedure were also identified. 
| Access creation
For the creation of a radiocephalic AVF, cephalic vein and radial artery diameters of 2 mm were considered appropriate for fistula creation.
For the creation of brachiocephalic AVF and basilic vein transposition, vein diameters and brachial artery diameters of 3 mm were considered appropriate for fistula creation. For AVG creation, a standard wall PTFE graft (Gore-Tex, WL Gore & Associates, Flagstaff, Arizona) with 6 mm diameter and 0.5 mm wall thickness was used in a forearm loop configuration, vein diameters of 4 mm were considered appropriate.
All anastomoses were created with a running polypropylene 6-0 suture (Prolene ® , Ethicon Inc., Somerville, NJ).
| Indication for thrombectomy
In case of suspected vascular access thrombosis, patients were 
| Thrombectomy procedure

| Definitions
Technical success was defined as the restoration of blood flow, combined with a residual stenosis of less than 30%, as reported by the Society of Interventional Radiology. 14 Stenosis was defined as the presence of a peak systolic velocity greater than 310 cm/s in AVG and greater than 375 cm/s in AVF, with a vessel diameter smaller than 2.0 mm. 15 Indications for interventions were standardized; in patients with an AVF with flow rates <500 ml/min and patients with an AVG with flow rates <600 ml/min, or with a consistent monthly decrease of 25% or more with a flow rate < 1,000 ml/min, angiography was scheduled and a percutaneous transluminal angioplasty (PTA) was performed in the case of stenosis. 1 
| Follow-ups
| AngioJet™ procedure
Results and specifications of AngioJet™ procedures are shown in 
| Patency
Primary, primary-assisted, and secondary patency rates are shown in Figures 1-3 . A significantly higher primary patency rate after the Angiojet™ system was found for the AVF group than for the AVG group (p < .001). Also, primary-assisted patency was significantly higher in the AVF group than in the AVG group (p = .001). Secondary patency rates were comparable between the two groups (p = .262).
The results of univariate analysis of factors influencing patency are shown in Table 3 . and compared with the AVG group, and success rates were not specified for AVF patients. 8 Experience and comparison of different endovascular thrombectomy devices in AVF is described by Yang et al. 9 The AngioJet™ thrombectomy device was compared with the Arrow-Trerotola™ percutaneous thrombectomy device (PTD) in 275 thrombectomy procedures in patients with occluded AVF. They concluded that the PTD had a significantly higher success rate than the AngioJet™, 91% versus 76% (p = .002), with analogous patency rates. Our clinical success rate with the AngioJet™ did resemble the clinical success rate of the PTD group in their study; the patency rates were likewise similar. This might be explained by the type of AngioJet™ catheter, as only 31 of the 134 procedures were performed with the latest, more powerful AVX catheter.
A recent systematic review compared the outcomes of different endovascular devices in percutaneous treatment of thrombosed vascular access, mainly divided into two categories: thrombectomy dependent and thrombolysis dependent. No significant differences were found in vascular access survival between the different treatments. However, a shift toward thrombectomy-dependent devices to reduce the amount of hemorrhagic complications associated with thrombolytic drugs was observed over time. 5 The strength of this study is that we provide detailed information about the procedures and outcomes with the latest AngioJet™ system, especially in occluded AVFs. Patency rates were compared between AVF and AVG groups and multivariable analysis was performed to define predictors for failure after treatment. Limitations of the current study are its retrospective nature and the fact that the total number of included AVFs was relatively small compared with the included AVGs.
| CONCLUSIONS
Based on the results of our retrospective study, the AngioJet™ system can be deemed an effective technique to reestablish patency in occluded vascular access, with minimal use of central venous catheters for dialysis. Good technical and clinical success rates were achieved with acceptable patency rates, which improved in patients with an AVF compared with patients with an AVG. Furthermore, this study identified several factors that influenced patency after the AngioJet™ thrombectomy procedure.
